Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation

Stroke

Volumn 27, Issue 7, 1996, Pages 1163-1166

  Fisher, Mark ^a   Fernández, José A ^b   Ameriso, Sebastian F ^a   Xie, Dangci ^a   Gruber, Andras ^b   Paganini Hill, Annlia ^a   Griffin, John H ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

cerebral ischemia; Hispanic Americans; protein C; thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5; GLUTAMINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; SCREENING; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0029886290     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.7.1163     Document Type: Article

References (39)

1. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
2. Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982;59:1067-1072.
3. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1006.
4. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993;82:1989-1993.
5. Koster T, Rosendaal FR, deRonde H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993; 342:1503-1506.
6. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
7. Hallgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995; 173:210-213.
8. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, deRonde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
9. 506Gln mutation in factor Va. Lancet. 1994;343:1361-1362.
10. 506 of factor V. Lancet. 1994;343:1535-1536.
11. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.
12. Sun X, Evatt B, Griffin JH. Blood coagulation abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 1994;83;3120-3125.
13. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V(R506Q). J Biol Chem. 1995; 270:4053-4056.
14. 506-factor V. Blood. 1995;85:3405-3411.
15. Halbmayer W-M, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 1994;5:51-57.
16. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance. Stroke. 1995;26:885-890.
17. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
18. 506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995;73:558-560.
19. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Anerioscler Thromb Vasc Biol. 1995;15:783-785.
20. Lalouschek W, Suess E, Aull S, Schnider P, Uhl F, Zeiler K, Pabinger-Fasching I. Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke. Stroke. 1995;26:1963-1964. Letter.
21. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996;27:44-48.
22. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport S. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood. 1995;84:1704-1711.
23. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-1134.
24. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995;74:449-453.
25. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Steering Committee. North American Symptomatic Carotid Endarterectomy Trial: methods, patient characteristics, and progress. Stroke. 1991;22:711-720.
26. Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickenson JP, Kieffer G, Sakariassen KS. Clooidogrel: a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost. 1994;71:655-662
27. 506-factor V. Thromb Res. 1995;80:441-443.
28. Griffin JH, Heeb MJ, Kojima Y, Fernández JA, Kojima K, Hackeng TM Greengard JS. Activated protein C resistance: molecular mechanisms. Thromb Haemost. 1995;74:444-448.
29. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Thromb Haemost. 1995;74:139-148.
30. Vasse M, Leduc O, Borg J-Y, Chrétien MH, Monconduit M. Resistance to activated protein C: evaluation of three functional assays. Thromb Res. 1994;76:47-59.
31. Bokarewa MI, Bremme K, Falk G, Sten-Linder M, Egberg M, Blombäck M. Studies on phospholipid antibodies, APC resistance and associated mutation in the coagulation factor V gene. Thromb Res. 1995;78:193-200.
32. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;334:1453-1457.
33. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis Thromb Haemost. 1996;75:393-394.
34. Gillum RF. Epidemiology of stroke in Hispanic Americans. Stroke. 1995;26:1707-1712.
35. Macko R, Gruber A, Griffin J, Ameriso S, Barndt R, Weiner J, Wong V, Fisher M. Low circulating activated protein C levels in ischemic stroke. Thromb Haemost. 1993;69:626. Abstract.
36. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood. 1986;67:362-365.
37. Wong V, Hofman F, Ishii H, Fisher M. Regional distribution of thrombomodulin in human brain. Brain Res. 1991;556:1-5.
38. Snow TR, Deal MT, Dickey DT, Esmon CT. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation. 1991;84:293-299.
39. Phillips DJ, Greengard JS, Fernández JA, Ribeiro M, Evatt BL, Griffin JH, Hooper WC. Protein S, an antithrombotic factor, is synthesized and released by neural tumor cells. J Neurochem. 1993;61:344-347.